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Extracellular vesicles (microvesicles), such as exosomes and shed microvesicles, contain a variety of molecules including proteins,
lipids,andnucleicacids.Microvesiclesappearmostlytooriginatefrommultivesicularbodiesortobudfromtheplasmamembrane.
Here, we review the convergence of microvesicle biogenesis and aspects of viral assembly and release pathways. Herpesviruses and
retroviruses, amongst others, recruit several elements from the microvesicle biogenesis pathways for functional virus release. In
addition, noninfectious pleiotropic virus-like vesicles can be released, containing viral and cellular components. We highlight
the heterogeneity of microvesicle function during viral infection, addressing microvesicles that can either block or enhance
infection, or cause immune dysregulation through bystander action in the immune system. Finally, endogenous retrovirus and
retrotransposonelementsdepositedinourgenomesmillionsofyearsagocanbereleasedfromcellswithinmicrovesicles,suggestive
of a viral origin of the microvesicle system or perhaps of an evolutionary conserved system of virus-vesicle codependence. More
research is needed to further elucidate the complex function of the various microvesicles produced during viral infection, possibly
revealing new therapeutic intervention strategies.
1. AnIntroductiontoExtracellularVesicles
Awidevarietyofvesiclesareactivelyreleasedfromlivingcells
into the extracellular space with their contents reﬂecting the
cellularcompositionandphysiologicstate(forreviewsee[1–
3]).Overtheyears,thediﬀerenttypesofextracellularvesicles
havebeengivenavarietyofnames,includingexosomes,shed
microvesicles, ectosomes, microparticles, virosomes, virus-
like particles, and oncosomes. The distinguishing features of
each of the vesicle subtypes and the correct nomenclature
are currently under intense study. Here, we will refer to
them under the general term, microvesicles. Microvesicles
carry RNA [mRNA, microRNA (miRNA), and noncoding
sequences], cDNA and genomic sequences, and a large
component of proteins and lipids (see reviews above, as well
as [4, 5]). Upon release these microvesicles can move within
theextracellularspaceandareeithertakenupbyneighboring
cellsordegraded.Theycanalsoenteradjoiningbodilyﬂuids,
such as the systemic circulation and travel to distant sites.
In fact, they have been found in abundance in blood (serum
and plasma), urine, breast milk, sweat, saliva, ascites ﬂuid,
and cerebral spinal ﬂuid (CSF) [3–7]. At least two distinct
release mechanisms for microvesicles have been described
for two subtypes: (1) exosomes—derived from the multi-
vesicular body (MVB) and (2) shed microvesicles—derived
from the plasma membrane. Interestingly, both mechanisms
have considerable overlap with virus release and biogenesis
(summarized in Figure 1 and further discussed below).2 Advances in Virology
Exosomes range from 30 to 100nm in diameter and are
generated by inward budding of the lumen of internal vesic-
ular compartments derived from endosomes [8]. As vesicles
accumulate within these endosome-derived compartments,
they are referred to collectively as MVBs. These MVBs can
either be targeted for degradation through the lysosomal
pathway, or they can fuse with the plasma membrane
releasing their interior vesicles into the extracellular space.
Theexactmechanismandkineticsofthesefusionandrelease
events are not fully elucidated and may vary among diﬀerent
cell types [9]. For example, depletion of Hrs (an ESCRT-
0 component) led to a decrease in exosome secretion in
dendriticcellsthatwerestimulatedtoreleasewithovalbumin
and a calcium ionophore [10]. Oligodendrocytes on the
other hand seem to secrete exosomes by a mechanism that is
ESCRT independent and ceramide dependent [11]. Exosome
release by HeLa cells has been found to involve Rab27a/b
[12], and p53 is reported to play a role in exosome release in
anonsmallcelllungcancercellline[13].Rab11hasalsobeen
shown to be involved in the release of exosomes from MVBs
by acting in the tethering/docking of MVBs to the plasma
membrane to promote homotypic fusion, in the presence of
calcium [14]. In addition, TBC1D10A-C, a Rab35 inhibitor,
led to intracellular accumulation of endosomal vesicles and
impaired exosome secretion [15].
Shed microvesicles are released by outward budding
directly from the plasma membrane and tend to be larger
(>100nm in diameter) and more heterogeneous in size
[16, 17]. Moreover, this release process is likely controlled
by localized cytoskeleton dynamics, with small cytoplas-
mic membrane-covered protrusions detaching and being
released into the extracellular space [18]b ya na c t i v a t e d
GTPase, ARF6 [19]. Interestingly, recent observations indi-
cate that virus-independent budding from the plasma mem-
brane can be mediated by endosome to plasma membrane
relocation of TSG101, a prominent member of the ESCRT-
I complex, frequently noted as an exosome marker [20].
This type of budding is topologically identical to both the
inward budding of the limiting membrane of MVBs and
viral assembly at the plasma membrane, in that the outer
surface of the plasma membrane is on the outer surface of
the microvesicle. In fact, certain tumor cells shed retroviral-
like vesicles, which can be abundant because of increased
transcription of endogenous retroviral sequences [17, 21],
resulting from overall hypomethylation of the genome [22].
In general it seems that the clear distinctions between viruses
a n dm i c r o v e s i c l e sb a s e do nc o m p o s i t i o na n df u n c t i o na r e
fading although they can be separated from vesicles released
during the later stages of programmed cell death since these
latter vesicles, referred to as apoptotic blebs [2], are even
larger in size [23].
The role of microvesicles in intercellular communication
is currently receiving much attention. Upon release from
the donor cell, the microvesicles can either be taken up by
neighboring cells or travel through bodily ﬂuids for cargo
delivery into recipient cells at distant sites. Although many
details are missing, cellular uptake of some microvesicles
appearstodepend,atleastinpart,onspeciﬁcligand-receptor
recognition [24], and can be mediated by direct fusion of the
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Figure1:Convergenceofmicrovesicleandvirusbiogenesis.Viruses
share eﬀectors of microvesicle production for their assembly and
release. Exosomes produced in the MVB and shed microvesicles
budding of the plasma membrane are indicated by blue and
yellow dots, respectively. Extrachromosomal herpesvirus genomes
are indicated by circles, retroviral genomes by sea-gull wings, and
retrotransposonsbytheYdrawing.Herpesviruses,retroviruses,and
retrotransposons sharing exosome or shed microvesicle pathways
are indicated by red, black, or Y-containing dots, respectively.
Chimeric virus-like vesicles are exosomes or shed microvesicles
containing viral or retrotransposon elements and are indicated in
dual color. N: nucleus, G: Golgi apparatus, MVB: multivesicular
body.
microvesicles with the plasma membrane or by endocytotic
uptake of the microvesicles. For example, Quah et al. [25]
have shown that bystander na¨ ıve B cells are rapidly activated
by acquiring the antigen from activated B cells through
microvesicle-mediated membrane transfer. In a similar way
CD41 is transferred from platelets to endothelial and tumor
cells, resulting in increased proadhesive properties of the
recipient cells [26, 27]. Microvesicles also shuttle mRNA
between cells and inﬂuence the physiological state of the
recipientcell,aswellasthecellularresponsetoexternalstress
stimuli [28]. In addition, miRNAs are transferred by exo-
somes [6, 29, 30]. For instance, miR-146a was shown to be
transferred into recipient prostate cancer cells leading to the
inhibition of their proliferation [31], and recently miRNAs
which can modulate the immune response were detected in
exosomes in breast milk [32]. Furthermore, retrotransposon
sequences are particularly enriched in tumor microvesicles,
and tumor-derived human endogenous retroviral (HERV)
sequences can be transferred to normal human umbilical
vein endothelial cells (HUVECs) via microvesicles resulting
in a prolonged increase in HERV-K mRNA levels [17].
This suggests that tumor cells transfer these mobile genetic
elements via microvesicles to neighboring normal cells
thereby modulating their genotype and phenotype.Advances in Virology 3
2. VirusesandMicrovesicles
Microvesicular shedding of cellular membrane components
and the release of internal endosomal-derived exosomes are
important for cellular communication and modulation of
immune responses [9, 54–57]( Table 1). While release of
microvesicles has been extensively investigated, recently the
challenge has been to uncover the speciﬁc mechanisms that
guide protein sorting and complexing into shed microvesi-
c l e sa n de x o s o m e si nv a r i o u sc e l lt y p e s .C e l l sh a v eb e e n
reported to secrete highly speciﬁed microvesicles after infec-
tious exposure or under various cell activation conditions [5,
54,56,58].Throughthepackagingandtransferoffunctional
proteins, mRNA/miRNA, and other cytosolic components,
microvesicles have been found to be beneﬁcial either to the
host cell or to the infectious agent [37, 43]. Virus-infected
cells proved useful in early studies to elucidate the role
of microvesicular shedding in intercellular communication
[55, 56]. Amongst the most extensively studied viruses with
respect to microvesicles are herpes simplex virus (HSV),
human immunodeﬁciency virus (HIV), and the tumorigenic
herpes virus, Epstein-Barr virus (EBV). Each virus possesses
unique properties that aﬀord protection from immune
attack. Here, we outline the important immune modulatory
steps involved in virus-induced microvesicle sorting and
release in these and other related viruses. Preservation of
the virus depends on microvesicle release of infected cells.
Microvesicles released by infected cells contain speciﬁc com-
ponents of the cell and the virus, many of which facilitate the
abilityofvirionstopersistinahostileantiviralimmuneenvi-
ronment [44, 55, 56, 58]. Depending on the virus type, and,
in some cases, the stage in the viral cycle, intercellular pro-
cesses are well orchestrated to produce speciﬁc cellular and
immune outcomes [56]: (1) evading the host immune sys-
tem, (2) invasion, (3) replication, and (4) persistence (sum-
marized in part in Figure 2 and further discussed below).
2.1. Evading the Host Immune System. During primary
viral infection, humoral and cell-mediated host immune
responses such as production of neutralizing antibodies
and cytotoxic T-cell attack on infected cells are employed
to contribute to viral destruction. Early evasion strategies
adopted by viruses interfere with complete elimination of
the virus, allowing it to persist. During HSV-1 infection
the release of microvesicles, formerly known as L-particles
containing viral tegument proteins and glycoproteins, can
prime surrounding cells for productive infection and reduce
immune rejection [48–50]. Such virus-like vesicles lack both
the viral capsid and DNA and are thereby incapable of
producing a replication-infective cycle in the cells on their
own [49–51]. However, some of the viral tegument proteins
contained within them are immediate early transcription
factors that can produce rapid transcriptional activation of
laterarrivingintactvirions[48,52].Anotherevasionstrategy
observed for HSV-1 is targeting of the MHCII molecule
processing pathway by viral envelope glycoprotein B (gB)
[37]. Antigen-presenting cells (APCs) routinely sort the
MHCII surface receptor HLA-DR to MHCII compartments
for processing. The primary role of this pathway is to present
Table 1: Selective overview of viruses and vesicle function.
Virus Immune status Vesicle origin Reference
HIV Activating CD8+ T cell [33]
HIV Activating Megakaryocyte [34, 35]
HIV Activating Dendritic cell [36]
HIV Evasion Infected cell [37–42]
CMV Evasion Infected cell [43]
EBV Evasion Infected cell [44–47]
HSV Evasion Infected cell [37, 48–53]
peptide antigens to the immune system in order to elicit
or suppress T-(helper) cell responses that stimulate B-cell
production of antigen-speciﬁc antibodies [37]. HSV-1 gB
couples with HLA-DR, causing sorting through the exosome
pathway as opposed to presentation on the cell surface.
Complexing of gB-DR eﬀectively hijacks the cellular antigen
presenting machinery, preventing further peptide loading
and,inaddition,increasingmicrovesicleproduction[37,53].
This ﬁnal step releases additional gB-DR complexes into
the host immune microenvironment, promoting resistance
of viruses to immune attack, and in some cases producing
bystander T-cell tolergenicity or anergy [37, 53]. In the case
of HIV, microvesicle packaging and spread of the virus-
encoded Nef protein impairs proper endocytosis of the
immature MHCII/invariant chain, antibody class switching,
and lysosomal degradation of viral peptides allowing HIV
virus to evade immune recognition [37, 38]. EBV, human
cytomegalovirus (CMV) and hepatitis C virus (HCV) have
also found means to evade immune responses by exploiting
microvesicles, as discussed below.
2.2. Invasion and Replication within the Host Cell. Exosomes
and shed microvesicles can both incorporate elements from
the cell, as well as from the intruding virion [54]. Upon
circulation of these microvesicles, they encounter and enter
susceptiblecellsandcansensitizethemtoviralinfectionthus
increasing systemic spread of the virus to na¨ ıve cells. In the
case of the human CMV, microvesicles released by infected
cells present the C-type lectin family molecule expressed
on dendritic cells—used in capture and internalization of
pathogens—in complex with the CMV glycoprotein B. This
complex can be subsequently distributed to other cells
by microvesicles, thereby increasing the susceptibility of
these cells to CMV [59]. A similar mechanism is found
in the case of HCV. In HCV-positive patients, the cellular
membrane protein CD81 associates with one of the HCV
envelope glycoproteins, E2. Extracellular release of the E2-
CD81 complexes within microvesicles allows for increased
virus-fusing ability and infectivity of previously na¨ ıve cells
[60]. Microvesicles bearing the E2-CD81 complex and
containing HCV RNA are of notable importance as they
have been reported to be infectious even in the presence
of neutralizing antibodies [60]. Interestingly, HCV has been
shown to release three phenotypically distinct types of
microvesicles having variable infectivity from high to low
[60]. However, diﬀerential release of these microvesicles
during HCV pathogenesis remains to be elucidated.4 Advances in Virology
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Figure 2: Heterogeneity of microvesicle function during virus
infection. Microvesicles with diverse eﬀects on virus spread are
indicated by diﬀerent colors. Microvesicles from infected cells can
aﬀect noninfected cells, enhancing infection, or killing incoming
immune cells, or act to activate immune cells to viral antigens.
Microvesicles from noninfected cells can either enhance or block
virus release from the infected cell and modulate the immune
response. Cell with dashed lines is undergoing cell death.
2.3. Microvesicles Contribute to Host Immunity against Viral
Infection. Conversely, microvesicular release can contribute
to viral attack by the host immune system. For example, in
early invasion steps of CMV, CMV antigens are transferred
frominfectedepithelialcells(ECs)viaEC-derivedmicrovesi-
cles to APCs [43]. These APCs are not detected as infected
cells but are rendered more susceptible to infection with
subsequent encounters with the virus [43] .W h i l et h i si sa
primary infectious viral invasion and replication strategy,
inadvertently transferred APCs bearing CMV antigens in
transplanted organs serve as markers to the host immune
systems to target nonself tissue. Harboring of these suscepti-
ble APCs by the immune-compromised host and continued
microvesicular shedding increases T-cell surveillance and
inﬂux into the grafted tissues, thereby exacerbating allograft
rejection [43]. Microvesicles can also promote the innate
immune response to viruses, for example, as observed for
HIVwherebytransferofaparticularantiviralcytidinedeam-
inaseviaexosomesinhibitsHIVreplication[61].Inaddition,
virus-like vesicles can be used as a vaccination strategy, and
recently chimeric virus-like vesicles were engineered using a
mixtureofcoronavirusandinﬂuenzaproteinsfunctioningas
a potential severe acute respiratory syndrome (SARS) virus
vaccine [62].
2.4. Further Applications. Viruses can use various microvesi-
cle transport mechanisms as a survival strategy, while in
other cases the host immune system can utilize microvesicles
for cell signaling and host protection. Microvesicles can
directly activate or suppress cellular responses, induce or
facilitate infection, and transfer material to improve or
hinder host immune recognition [9]. These same strategies
canbeexploitedinthedevelopmentofvirus-basedtherapies.
Oncolytic viruses armed with therapeutic genes are currently
being evaluated for safety and eﬃcacy for cancer therapy
[63–65]. It would be of interest to determine whether
microvesicles can alter the eﬃcacy of oncolytic viruses, and
other types of viral gene delivery vectors. Recent work shows
that microvesicles can be loaded with adenoassociated viral
(AAVs) vectors for more eﬃcient gene delivery [66], opening
a new window into the microvesicle therapeutics ﬁeld.
3. EBV andMicrovesicles
Several human pathogenic viruses are known for their ability
to lie dormant in the host immune system, of which HSV
and EBV are perhaps the best known examples. In the case
of HSV this is due to the ability of the virus to enter a
latent state in the nucleus of sensory neurons during which
it expresses no viral antigens and does not disturb the
physiology of the neurons. In latency a single transcript is
generated which encodes a precursor for four distinct HSV,
miRNAs which act to suppress virus replication [67]. For
human herpesvirus 4 (HHV4), better known as EBV, this is
largely due to incomplete eradication of the virus after early
primary infection.
Gamma herpesviruses, including EBV, have developed
a variety of strategies to exploit host-cell regulatory path-
ways that lead to a permanent infection of their host.
When these pathways are deregulated, what is usually an
undamaging herpes infection can predispose to disease-
including encephalitis, autoimmunity, and cancer [68]. It
was recently demonstrated that EBV exploits the endosomal-
exosomal pathway by balancing intracellular signaling in
infected B cells [69] and controlling epigenetic changes
in uninfected neighboring cells via microvesicles [30].
Enveloped viruses of the herpes virus family, such as
human CMV (HCMV/HHV5) and EBV, depend on the
interaction with cellular endosomal membrane systems
for replication [70]. Interestingly, mature HHV-6 virions
are released together with internal vesicles through MVBs
by the cellular endosomal-exosomal pathway [71]. Thus,
many herpesviruses generally seem to exploit endosomal
pathwaysandmicrovesiclesforvirusproduction,release,and
immune evasion. However, the ﬁnding that viruses such as
EBV modulate host-cellular pathways that are not directly
involved in virus production needs further investigation.
Being the ﬁrst human tumor virus identiﬁed, EBV is in
many aspects an extraordinarily benign pathogen and is best
known as the causative agent of “kissing disease” or infec-
tious mononucleosis. It is estimated that over 90% of the
world population is persistently infected with EBV. The EBV
life cycle begins by exchange through saliva and EBV virions
that seem to preferentially infect na¨ ıve resting B cells in
secondary lymphoid organs, such as the tonsils. Occasionally
isolated epithelial cells also become infected and presumably
sustain lytic replication [72], which is required for viral
shedding into the saliva for transmission to new hosts [73].Advances in Virology 5
To reach its near universal prevalence without harming
the host, EBV and related persistent herpesviruses have
evolvedcomplexstrategiesencouragingimmunerecognition
in proliferative (potentially oncogenic) stages of its life cycle,
while elegantly avoiding the immune recognition at other
stages by “going into hiding” [74]. Upon initial infection
at the mantle zone of germinal centers (GCs), the newly
infected na¨ ıve B cells undergo multiple diﬀerentiation stages
and tight interactions with surrounding stroma and T cells
[75]. Interestingly, EBV facilitates these essential interactions
for the maturation of B cells, for instance, by upregulation
of crucial GC reaction-associated proteins, such as GP183
[76]. This integral part of the EBV life cycle (i.e., mimicking
a GC-type reaction) requires tight growth regulation in
a speciﬁc EBV latency gene expression program (Latency
III) and promotes rapid growth and proliferation of these
infected cells through NFκB activation. This strategy in
expanding the infected pool of B cells without the need
for lytic replication may be advantageous under normal
conditions but raises the chances of turning-on malignant
growth if the viral latency programs are not properly
controlled. Indeed, if these cells do not progress further into
memory cells by shutting down this growth program, they
can remain in the proliferative phase and give rise to EBV-
positive lymphomas which can kill the host, thus, restricting
further viral propagation and spread [77]. In addition, EBV
infection at this stage may also predispose to autoimmunity
as inappropriate survival signals may interfere with negative
selectionofself-reactiveBcells.Ofnote,immune-suppressed
individuals are at increased risk for developing EBV-driven
lymphomas, reﬂecting the importance of a lifelong potent
anti-EBV T-cell response [78]. The ability of EBV to persist
despite such vigorous T-cell responses indicates that EBV
can escape from the adaptive immune system and may do
so in part by exploiting the endosomal-exosomal pathway
through the secretion of T-cell inhibitory exosomes [44–
46]. When secreted by EBV-positive tumors, these exosomes
carry immune-evasive proteins including the viral protein
LMP1 [79] and high amounts of galectin 9 that cause
massive apoptosis of EBV-speciﬁc CD4+ T-cells via speciﬁc
interaction with T-cell immunoglobulin mucin-3 (Tim-3),
which can negatively regulate Th1 T cell and macrophage
activation. The inhibition of anti-EBV immune responses
is believed to promote the progression of EBV-positive
malignancies, such as Hodgkin’s disease (HD) [46]a n d
nasopharyngeal carcinoma (NPC) [80].
Vallhov et al. [81] studied the interaction between
exosomes secreted by EBV-driven lymphoblastoid cell lines
(LCLs) and peripheral blood B cells proliferating in vitro.
LCLs are 95% latent, but a small proportion of cells is in
a lytic stage. Exosome-cell interactions could be inhibited
by speciﬁc antibodies against gp350 the major envelope
protein of EBV or CD21 on B cells, indicating an interaction
between CD21 on B cells and the gp350 on exosomes [81].
These speciﬁc exosome-cell interactions may be exploited
for exosome-based anticancer therapies, for example, in
delivering the CD154 protein to leukemic B blast cells
rendering them immunogenic to T cells [82]. In addition
to proteins, it is now clear that microvesicles from many
cell types carry and transport functional RNA molecules.
EBV was the ﬁrst virus discovered to encode its own small
regulatory miRNAs [83]. EBV encodes a staggering 44 viral
miRNA species, derived from two major gene clusters on
the viral genome, which have an important role in EBV
persistence [84]. Next generation sequencing indicates that
these EBV-encoded miRNAs make up a large fraction (20–
25%) of the total cellular miRNA in EBV-infected cells,
encompassing 300+ diﬀerent miRNA species [85]. Similar
results were found in the miRNA proﬁle of exosomes from
EBV-drivenLCLcells(Pegteletal.,unpublishedresults).This
is consistent with the idea that viral miRNAs manipulate
gene regulation in host cellular pathways and also exploit the
exosomal miRNA communication pathways.
Indeed, the discovery of EBV-encoded regulatory miR-
NAs (EBV-miRNAs) residing within the lumen of exosomes
indicated a novel mechanism by which exosomes can exert
inhibitory eﬀects, namely, by translational repression of
target genes in noninfected recipient cells via exosomal
EBV miRNAs [30]. Earlier studies in mice had suggested
that intact exosomes from EBV-infected cells had strong
physiological eﬀects in vivo, consistent with the idea that the
luminal content of exosomes is biologically signiﬁcant, apart
from the proteins and lipids that make up their surface [86].
Subsequent studies demonstrated that EBV-infected cancer
ECs also secrete EBV-miRNAs, presumably within exosomes
[87]. Due to the lack of an accurate in vivo model for human
EBV infection it is diﬃcult to investigate the mechanism
controlling release of EBV-miRNAs through exosomes and
to determine whether this contributes to viral persistence in
healthy infected individuals. However, EBV-encoded miR-
NAs are transported from infected B cells to noninfected
(EBV-DNA negative) T cells and monocytes, supporting the
idea of horizontal miRNA transfer in humans. Thus, viral
miRNAs in exosomes may contribute to sustain persistent
virus infection by delivery of such miRNAs into noninfected
responding T cells leading to their inactivation (anergy)
[45]o rd e s t r u c t i o n[ 44]. This is consistent with recent
data suggesting that exosomes eﬃciently transport miRNAs
through the immunological synapse during interactions of T
c e l l sw i t hA P C s[ 47], similar to what is known concerning
antigen exchange [88]. Studies are underway to establish
whether EBV exploits these specialized intercellular con-
tacts for eﬃcient posttranscriptional control in neighboring
responding immune cells as a possible mechanism for
immune escape.
4. HIVand Microvesicles
HIV [56, 89–91] has been a discussion topic in the
microvesicle ﬁeld for many years. Not only has it been
hypothesized that HIV itself may have microvesicle features,
but microvesicles also have been described to have immune
modulatory functions on HIV-infected cells and to expand
the infectivity of HIV.
In 2003 Gould et al. [92] postulated that HIV—an
enveloped retrovirus—hijacks the microvesicle system to
beneﬁt its own assembly and subsequent exit. Interestingly,6 Advances in Virology
inhibitors were identiﬁed that blocked the budding of both
shed microvesicles and HIV particles [93]. In addition,
peptides were identiﬁed that prevented interactions of
HIV Nef protein—a key protein in the HIV life cycle—
with mortalin, a cellular heat shock protein, and resulted
in inhibition of the release of HIV and Nef-containing
microvesicles [94]. Careful analysis, however, has indicated
that although HIV exploits certain proteins that also play a
role in exosome formation via the MVB [95], HIV assembly
does not necessarily use the same logistics system as do
exosomes. Importantly, it has been established that HIV
budding occurs mostly at the plasma membrane and not
from within the MVB [96–99]. Interestingly, HIV recruits
members of the MVB ESCRT complex for proper HIV
budding from the plasma membrane [98–102]. While in
CD4+ T cells HIV release appears to be independent of
exosomes [103], in monocyte-derived macrophages HIV can
bud into endosomes [102, 104]. However, several studies
highlight that HIV-1 budding also in macrophages occurs
primary at the plasma membrane [105–107]. Thus, the
controversy about the site of productive virus assembly
in macrophages mostly favors the plasma membrane. HIV
release in dendritic cells may be triggered by signals similar
to those for exosome release [102, 108, 109], and secretion
of HIV from endocytic compartments in dendritic cells can
resultinHIVreleaseuponinteractionwithTcells[110,111].
However, these endocytic compartments were also described
to be connected with the extracellular space [112, 113]a n d
suggested to be invaginated domains distinct from classical
endocytic vesicles [114]. Moreover, microvesicle release from
T cells treated with ceramide inhibitors was not aﬀected
by such treatment [111], as previously reported for HIV-
1[ 115]. However, both viruses and microvesicles produced
from ceramide-deﬁcient cells failed to be captured by mature
dendritic cells [111]. Therefore, more research is warranted
on the speciﬁc sites of HIV assembly in particular cell types,
and to what extent the endosomal compartments play a role
in the HIV life cycle, as well as the possible convergence of
HIV and shed microvesicle pathways.
It seems likely that HIV has simply adapted to use certain
host factors for diﬀerent exit modalities, and that these may
vary among diﬀerent types of cells, as well as under diﬀerent
conditions. It will be of continuing interest to further study
the retroviral family, including the endogenous retroviruses,
inordertodeterminewhetherthemicrovesiclecargosystems
are perhaps a remnant of previous retroviral infections that
happened earlier in evolution—and elements of which are
now used in an opportunistic setting by retroviruses, such
as HIV [56, 89–91, 102] .T h i so v e r l a pi np a t h w a y sa n d
the consequence of using overlapping machinery for release
can result in phenotypic similarities between microvesicles
and retroviruses and potentially interfere with anti-HIV
strategies. For instance, HIV released from T cells has similar
glycome properties as T-cell microvesicles, arguing for a
common origin and indicating phenotypic similarity [116].
More research in the convergence of microvesicle and HIV
pathways may improve our understanding of these processes
and propel the development of new antiviral drugs directed
against HIV.
The role of microvesicles during HIV infection has not
yetbeenextensivelystudied,buttheyappeartobeinvolvedin
both HIV infectivity enhancement and resistance depending
on the cells of origin. Microvesicles derived from HIV-
infected cells have been reported to contain HIV CCR5
coreceptors, allowing for enhanced HIV infection of other
cells [34]. Moreover, microvesicles from megakaryocytes
and platelets contain CXCR4 and upon transference confer
susceptibility to cells normally resistant to HIV infection
[35, 117]. In addition, during HIV replication the HIV
Nef protein can alter the exosomal pathway by increasing
the number of intracellular vesicles and MVBs [118–121].
HIV Nef-induced microvesicle release from infected and
noninfected cells [39, 40] can induce apoptosis in CD4+
T cells [41] and convey resistance to HIV infection [61].
The transfer of Nef or other viral components through
microvesicles may represent an important mechanism for
immune evasion by viruses. In addition, exosomes can
contain APOBEC3G, a cytidine deaminase that is part of
the cellular antiviral system against retroviruses, which upon
transference to recipient cells via exosomes can inhibit HIV
replication [61]. While CD45, CD86, and MHC Class II
molecules have been found in microvesicles from HIV-
infected cells [42], possibly serving to silence the immune
response, microvesicles derived from CD8+ T cells can act
to suppress HIV replication [33]. Moreover, exosomes in
association with HIV derived from dendritic cells signif-
icantly enhance HIV infection of CD4+ T cells [36]. In
conclusion, microvesicles from HIV-infected cells as well
as from noninfected cells play an important role in HIV
replication and dissemination. Therefore, interference with
microvesicle-mediated signaling could possibly be harnessed
to halt HIV infection.
5. Retrotrasposon Elements and Microvesicles
Retrotransposon elements such as LINE, Alu, and human
endogenous retroviruses (HERVs) make up about 45% of
the human genome and have played an important role in
genome evolution [122]. These viral-like elements infected
germ cells in the human genome millions of years ago and
then became a stable part of the inherited genetic material.
Although most LINE elements are inactive, a number of
active ones remain and are able to “jump” to new locations
in the genome, contributing to genomic instability [123].
T h e s ee v e n t sc a nh a v ei m p o r t a n te ﬀects on our genome,
for example, by inactivating genes, altering gene expression
and facilitating random insertion of new cDNA copies in the
genome,asinintegrationofpseudogenes[124].Manytumor
cells also release retroviral-like microvesicles that contain
active retrotransposon sequences, such as HERV-K [125].
Recently, tumor-derived microvesicles have been shown
to be enriched in retrotransposon elements such as LINE1,
Alu, and HERV-K [17]. Furthermore, HERV-K was trans-
ferred through microvesicles to normal HUVECs, which
then showed an increase in HERV-K levels 12 hours fol-
lowing exposure to tumor microvesicles. In addition, the
mouse retroviral RNA VL30 is packaged in retrovirus vectors
by mouse packaging cell lines and transferred to humanAdvances in Virology 7
cells infected with those vectors [126]. The mouse VL30 has
several stop codons in the regions encoding for genes such
as gag, pol and env, thereby inhibiting its ability to encode
functional proteins [126]. However, transfer of the VL30
mRNA together with tissue factor (TF) to human melanoma
cells served to induce their metastatic potential. This change
in phenotype apparently occurs through formation of a
complex with the protein-associated splicing factor (PSF)
protein which represses transcription of an insulin-like
growth factor-1 (IGF-1) inducible gene, with dissociation
of this complex allowing transcription to proceed [126].
Three of the 11 human genes aﬀected by VL30 mRNA were
oncogenic, suggesting that the transfer of retroviral RNA
sequences can have catastrophic eﬀects on recipient cells.
Song et al. [126] have identiﬁed human retrotransposon
sequences that are >90% identical to the mouse VL-30
suggesting human VL-30 transferred through microvesicles
could have similar eﬀects on transcription [126].
Long interspersed elements (LINEs)—most notably
L1—comprise about 17% of the human genome. Several
studies indicate that a subset of L1 elements is still actively
expanding in the number of sequences within the human
genome by retrotransposition. This active subpopulation,
termed transcriptionally active (Ta), is approximately 2
million years old, and it has high levels of insertional
polymorphism in the human population [127, 128]. Some
of these new insertions may be intolerable and lethal and
therefore eliminated; others may result in phenotypically
tolerable disease, such as in Coﬃn-Lowry Syndrome and
choroideremia [129–131], while still others have been asso-
ciated with the induction of cancer, for example, lung cancer
[132]. The high level of polymorphism of L1 elements
indicates that they continue to have profound eﬀects on
the human genome, and recent evidence suggests that
microvesicles may be a potential route of delivery for these
elements [17]. This microvesicle-mediated Trojan Horse-like
[92] transferance of transposons could perhaps allow for a
stealthy dissemination of retrotransposons, especially in a
tumor setting, avoiding immune-recognition, and achieving
“long distance” delivery.
HERVs also entered the human genome millions of
years ago and comprise about 8% of the human genome.
They consist of gag, pol, and env sequences, ﬂanked by
two long terminal repeats [133]. Most of these sequences
are now silent because of acquired mutations and deletions
over the course of evolution, but HERV-K113 can produce
intact, albeit noninfectious, retroviral particles [134]. Some
of these sequences are still transcriptionally active and are
associatedwithdiseases,suchaslymphomaandbreastcancer
[21, 135]. In cancer, hypomethylation of the genome seems
to predominantly aﬀect retrotransposon sequences (perhaps
because they are highly abundant in the human genome),
allowing increased transcription, especially in the case of
the most recent entrants, which also happen to be the
elements with the most intact coding potential [136]. Indeed
retroviral-like microvesicles have been found in cancer
patients, notably those with lymphomas [21], breast cancer
[137], and teratomas [138]. As expected, these patients also
had high levels of reverse transcriptase, and viral gag and
env proteins and RNA in the tumor cells and retrovirus-like
microvesicles released from them into the circulation [21].
Tumor microvesicles from cultured tumor cells also have
been shown to be enriched in retrotransposon RNA, DNA,
and reverse transcriptase, suggesting that a subpopulation of
these microvesicles may indeed be of retroviral origin [19].
6. Concluding Remarks
In summary, this review deals with how extracellular
vesicles—such as exosomes and shed microvesicles—share
pathways with the assembly and release of retrotransposon
elements and viruses. In Figure 1 we summarize how her-
pesviruses such as EBV and HSV, originate from the nucleus
and can merge with microvesicle pathways. Several proteins
used for exosome production are used by herpesviruses for
functional release. Also, the convergence of these pathways
may explain the observations of virus-like particles, which
can be exosomes or shed microvesicles containing viral
proteins or nucleic acids. Similar observations have been
made for retroviruses and retrotransposon elements with
circulating microvesicles containing retrotransposon RNA
found in some cancer patients. It remains to be investigated
towhatextentexosomesandshedmicrovesiclesareremnants
ofpreviousretroviralcolonization.Inthisreviewwenotethe
observationsofretroviralaswellasretrotransposonelements
in microvesicles, perhaps allowing further dissemination of
such nucleic acid sequences. The use of microvesicle pathway
elements by viruses such as HIV may be suggestive of an
intricate coevolution of diﬀerent endogenous and exogenous
(retro)virus subtypes. Viruses not only use microvesicle
pathways for their own assembly and release but are also
capable of exploiting the highly complex microvesicle com-
munication system in an intercellular setting as simpliﬁed
in Figure 2. During viral infection microvesicles can have
various eﬀects on diﬀerent types of cells, either limiting viral
infection or enhancing it. Thus, a picture is emerging that
viruses and microvesicles are codependent pleiotropic enti-
ties. More research is needed into the diﬀerential functions
of diﬀerent subtypes of microvesicles and their cross-talk
in relation to the immune response and outcome of viral
infection.
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